EUVIMEDEUVIMED entdecken
Crossref

L26/P-509 Progesterone vaginal gel monotherapy versus combined regimen for luteal support in HRT-FET: equivalent pregnancy outcomes but differential predictive utility of serum progesterone

N. Li, J. Shi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N. Li und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does progesterone vaginal gel 180 mg/d monotherapy yield comparable ongoing pregnancy rates to combination therapy in HRT-FET cycles? Summary answer Progesterone vaginal gel 180 mg/d achieved equivalent ongoing pregnancy rates to combination therapy, with serum progesterone predicting pregnancy only in the monotherapy group. What is known already Vaginal progesterone is widely used for luteal phase support in FET cycles. While various progesterone formulations and dosing regimens exist, the optimal approach remains debated. Previous studies have explored the relationship between serum progesterone levels and pregnancy outcomes, but the predictive value of progesterone measurements across different luteal support regimens has not been systematically investigated. Study design, size, duration This single-center, randomized pilot trial (ChiCTR2000034113) enrolled 198 women aged 20-40 years undergoing their first single-blastocyst HRT-FET cycle from March to December 2021. Participants were randomized 1:1 to receive either progesterone vaginal gel 90 mg twice daily (180 mg/d, n = 97) or progesterone vaginal gel 90 mg once daily plus oral dydrogesterone 10 mg twice daily (n = 99). All participants received GnRH agonist down-regulation prior to hormone replacement therapy. Participants/materials, setting, methods Women with endometrial thickness >8 mm and ≥2 good-quality blastocysts were included. Primary outcome: ongoing pregnancy at 12 weeks. Secondary outcomes included beta-hCG positivity, clinical pregnancy, live birth, miscarriage, and safety. Serum progesterone was measured on transfer day and day 12. Post-hoc analyses evaluated correlations between day-12 progesterone and ongoing pregnancy, including ROC analysis. Main results and the role of chance Ongoing pregnancy rates were comparable between groups: 57.73% (Monotherapy Group) versus 65.66% (Combination therapy Group) (OR 1.40, 95% CI 0.79-2.50; P = 0.254). Secondary outcomes including clinical pregnancy (67.01% vs. 72.73%, P = 0.383), live birth (56.70% vs. 63.64%, P = 0.321), and early miscarriage (13.85% vs. 8.33%, P = 0.302) showed no significant differences. Safety profiles were similar between groups. Critically, serum progesterone levels 12 days post-transfer correlated significantly with ongoing pregnancy in the monotherapy group (r = 0.337, 95% CI 0.052-0.571; P = 0.022), but not in the combination group (r = 0.037, P = 0.747). The interaction between treatment group and progesterone level was not statistically significant (P = 0.154), but the differential predictive patterns were clinically meaningful. ROC analysis in the monotherapy group identified 8.5 ng/mL as the optimal threshold for predicting ongoing pregnancy (AUC=0.695, sensitivity 69.2%, specificity 68.0%). Limitations, reasons for caution Single-center pilot study with limited sample size. Post-hoc progesterone analyses require confirmation. Different assay methods may affect threshold generalizability. The non-significant interaction test (P = 0.154) suggests cautious interpretation of differential predictive utility. Wider implications of the findings These findings challenge the assumption that combination therapy is superior to monotherapy for luteal support. Serum progesterone’s predictive value appears regimen-dependent, supporting individualized monitoring strategies: progesterone testing may guide dose optimization in monotherapy, whereas alternative approaches should be considered in combination therapy. Trial registration number Yes

Zitieren

APA

Li, N., & Shi, J. (2026). L26/P-509 Progesterone vaginal gel monotherapy versus combined regimen for luteal support in HRT-FET: equivalent pregnancy outcomes but differential predictive utility of serum progesterone. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.842

Vancouver

Li N, Shi J. L26/P-509 Progesterone vaginal gel monotherapy versus combined regimen for luteal support in HRT-FET: equivalent pregnancy outcomes but differential predictive utility of serum progesterone. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.842

BibTeX
@article{Li2026,
  author = {Li, N. and Shi, J.},
  title = {L26/P-509 Progesterone vaginal gel monotherapy versus combined regimen for luteal support in HRT-FET: equivalent pregnancy outcomes but differential predictive utility of serum progesterone},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.842}
}
Kostenlos starten →